



18L GAN 1655  
Box - SEQ  
#7  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**

In re Application of:  
Graeme I. Bell, *et al.*

Serial No.: 09/754,106

Filed: January 3, 2001

For: MUTATIONS IN THE DIABETES  
SUSCEPTIBILITY GENES  
HEPATOCYTE NUCLEAR FACTOR  
(HNF) 1 ALPHA ( $\alpha$ ), HNF-1 $\beta$  AND HNF-  
4 $\alpha$

Group Art Unit: 1655

JUN 08 2001

Examiner: J. SOUAYA

TECH CENTER 1600/2900

Atty. Dkt. No.: ARCD:272USC1/TJS

**CERTIFICATE OF MAILING**  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below.

June 4, 2001  
Date

*Jerome J. Schultz*  
Signature

**STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.825(a) AND (b)**  
**AND STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(g)**

**BOX SEQUENCE**

Commissioner for Patents  
Washington, D.C. 20231

Commissioner:

Submitted herewith is a substitute computer readable form and a substitute paper copy of the sequence listing of those sequences in the captioned patent application, wherein minor errors have been corrected. The substitute computer readable form of the sequence listing is the same as the substitute paper copy of the sequence listing. The sequence information provided in the

Specification is also the same as the sequence listing of the enclosed substitute computer readable and paper forms of the sequence listing.

In accordance with 37 C.F.R. § 1.821(g), it is herewith represented that no new matter is included with this submission.



FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 523-3020

Date: June 4, 2001

Respectfully submitted,



Teresa J. Schultz  
Reg. No. 40,526  
Attorney for Applicant